Patient reported frequency of lupus flare: associations with foundation makeup and sunscreen use by Squance, Marline L. et al.
Journal of Cosmetics, Dermatological Sciences and Applications, 2014, 4, 344-354 
Published Online December 2014 in SciRes. http://www.scirp.org/journal/jcdsa 
http://dx.doi.org/10.4236/jcdsa.2014.45046   
How to cite this paper: Squance, M.L., Reeves, G.E.M. and Attia, J. (2014) Patient Reported Frequency of Lupus Flare: Asso-
ciations with Foundation Makeup and Sunscreen Use. Journal of Cosmetics, Dermatological Sciences and Applications, 4, 
344-354. http://dx.doi.org/10.4236/jcdsa.2014.45046  
 
 
Patient Reported Frequency of Lupus Flare: 
Associations with Foundation Makeup and 
Sunscreen Use 
Marline L. Squance1,2,3,4,5*, Glenn E. M. Reeves1,3,4,5, John Attia1,4,5 
1Faculty of Health and Medicine, University of Newcastle, Callaghan, Australia  
2Faculty of Science and Information Technology, University of Newcastle, Callaghan, Australia  
3Autoimmune Resource and Research Centre, New Lambton Heights, Australia  
4Hunter New England Health District, New Lambton Heights, Australia  
5Hunter Medical Research Institute, New Lambton Heights, Australia 
Email: *marline.squance@hnehealth.nsw.gov.au  
 
Received 12 October 2014; revised 14 November 2014; accepted 3 December 2014 
 
Copyright © 2014 by authors and Scientific Research Publishing Inc. 
This work is licensed under the Creative Commons Attribution International License (CC BY). 
http://creativecommons.org/licenses/by/4.0/ 
  
 
 
 
Abstract 
Objective: To test the hypothesis that usage of foundation makeup (FM) and sunscreen lotion (SS), 
used individually or in combination, is associated with significant changes in the likelihood of lu-
pus symptom exacerbation. Methods: Self-reported flare days (SRF) and use of FM and SS products, 
were retrospectively examined in 80 Caucasian Australian women with ACR classified SLE for a 
year. Negative binomial regression modelled SRF days (outcome) against independent FMSS vari-
able and covariates: age; diagnosis years; outdoor hours; BMI; stress; immune therapy medication 
(ITM) use. Results: Statistically significant inverse associations between SRF days and FMSS use 
were found. Protective effects were statistically significant (p < 0.05) for combined FMSS exposure 
days (OR 0.998, CI 0.997 - 1.0) and FM alone (OR 0.603, CI 0.363 - 1.0). Significant associations 
consistent with increased SRF risk were seen in sub-analysis models for participants taking ITM: 
univariate model (OR 1.968, p = 0.03); multivariate model for FMSS (OR 2.11, CI 1.161 - 3.835); FM 
days (OR 1.855, CI 1.023 - 3.364). Results show SRF day reduction of 0.15% for each day of product 
exposure. Conclusion: Study results highlight protective effects of wearing FM with or without SS. 
This reduction in flare days ultimately has potential to improve quality of life in SLE patients. 
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1. Introduction 
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune illness characterised by multi-system involve-
ment that can be mild through to life threatening. SLE prevalence worldwide was recently estimated as 32 per 
100,000 [1], with potential for underestimation due to milder cases not being diagnosed [2]-[4]. Community 
burden of SLE, particularly in industrialised western countries and Caucasian populations, is reported to be on 
the increase, which cannot be attributed to improved diagnostic criteria and investigations alone [4].  
Environmental interactions along with intrinsic factors such as genetics, hormones and age have been reported 
as playing a role in SLE pathogenesis [5]-[7], with a small number of researchers suggesting that environmental 
exposures have a role in SLE progression and exacerbation patterns of sensitive individuals [5]-[10]. The inter-
play of endogenous and exogenous factors is thought to stimulate endocrine and immune regulatory systems in-
terfering with immune tolerance [3] [9] [11]-[13], manifesting in either suppression or heightening of immune 
system responses.  
The illness commonly exhibits periods of symptom quiescence and exacerbation (flare events). The unpre-
dictable nature of SLE flares reduces quality of life and has the capacity to reduce functional ability [13]. The 
numbers of SLE specific risk assessment studies investigating relationships between illness exacerbation and 
everyday products are limited. Stimuli such as UV exposure, certain pharmaceutical compounds, hormones, in-
fection and stress are the most researched and accepted triggers of flares [8] [14] [15]; however, in the majority 
of individuals, reasons for why and when flares occur remain unclear. Exposure to environmental agents in-
cluding personal hygiene and grooming products, which regularly contain solvents, phthalates, parabens, per-
fumes, UV filters and pigments [16] [17], is suggested as potential flare triggers.  
This study assesses the hypothesis that the use of common makeup products of foundation (FM) and sun-
screen lotion (SS), used individually or in combination, is associated with significant changes in the likelihood 
of self-reported flares (SRF) of lupus symptoms.  
2. Patients and Methods 
This study was a retrospective analysis of a cohort of 80 Caucasian female SLE patients as defined by the 
American College of Rheumatology (ACR) classification criteria for SLE [18]. Participants completed study 
specific questionnaires and interview to examine their flare experience and exposure to environmental products 
within daily living practices as part of a wider pilot study, “The Environmental Determinants of Lupus Flare 
(EDOLF)”. Data were of a self-reported nature over a 12 month study period capturing a full seasonal cycle.  
Methods have been reported previously in detail [19] and are briefly summarized here with methods specific 
to exposure and usage of foundation makeup (FM) and sunscreen (SS) outlined. Ethical review and approval 
according to Declaration of Helsinki 2008 [20] was granted from the University of Newcastle and Hunter New 
England Health Human Research Ethics Committees. 
2.1. Study Population 
Participants were recruited through the Autoimmune Resource and Research Centre (ARRC) and private Im-
munology clinics in the Hunter/Central Coast region of New South Wales, Australia. SLE diagnosis was con-
firmed through a health record audit to establish SLE diagnosis adhered to the ACR SLE Classification guide-
lines [18]. Due to minimal numbers of males meeting the ACR criteria, the final study cohort was limited to fe-
males only. The population was of a homogeneous Caucasian background. 
2.2. Data Collection  
Participants completed study specific questionnaires for assessment of medical history, home environment, and 
lifestyle practices as part of the wider EDOLF study. Of particular interest were participant patterns of commer-
cial product usage associated with personal hygiene and household cleaning practises. Participants also attended 
the ARRC for a clinical appointment where standard measures of health and their SLE flare history experience 
(SRF) were documented.  
2.2.1. Product Exposure Assessment 
Participants completed a Home Cleaning and Maintenance Product list (HCMPL) documenting all products used 
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within their home for cleaning and for personal care. The HCMPL collected the following product information: 
product type description, intended purpose of use, brand names and product usage over the study year. Exposure 
was calculated by combining count values of self-reported use of each product within a scale of “daily”, 
“weekly”, “monthly”, “yearly” and “don’t know”.  
The study goal was to examine common product use patterns and flare events; therefore, the developed 
methods did not direct participants to particular products or product categories. The HCMPL instructed partici-
pants to document all products used and stored within cupboards in various housing rooms (bathroom, kitchen, 
laundry, garages, etc.). Participants self-selected the products they documented without independent visual con-
firmation that all products had been documented. 
Product groups were categorised based on intended purpose of named product. The product category of 
“makeup” (FMSS) consisted of topical lotions of FM and SS only. Other makeup products such as lipsticks, eye 
shadow, mascara and colouring agents such as blush were self-reported by a small number of participants only, 
so they were not included within this analysis. As a crosscheck technique for products of specific interest, par-
ticipants were asked questions within the primary study questionnaire regarding FM and SS and their regime of 
use.  
Days of FMSS exposure was calculated for each participant as a total exposure day count by collating self- 
reported product/chemical exposure activity information and the specific product question responses from the 
primary study questionnaire. Duplication of individual products and usage day counts was avoided by cross-
checking data from each source. 
2.2.2. Patient Reported Flare Outcomes 
Flare assessment processes were not administered by a physician within a clinical review appointment, therefore 
traditional tools for assessing disease activity (e.g., SLEDAI) could not be used. To capture the lived experience 
of lupus, study flare event history was taken directly from the individual participant perspective and used stan-
dardisation scripted structured flare history interview [19] inclusive of a novel flare definition. The flare event 
definition chosen reflected a chronic autoimmune illness characterised by relapsing and remitting flare patterns 
whilst also incorporating the concept of symptom stability, punctuated by sustained exacerbation. 
An exacerbation is defined as: The appearance of a new clinical sign/symptom or the clinical worsening of a 
previous sign/symptom that had been stable for at least the previous 30 days and which persisted for a minimum 
of 24 hours [21]. 
SRF days were a calculation of self-reported number and average length of SRF events reported in the study 
period. Final analysis did not include participants that reported a “constant” state of flaring.  
2.2.3. Risk Factors 
Study specific questionnaires completed included information on participant demographic, medical history, 
general health and wellbeing. Each participant nominated an approximate date of their SLE diagnosis which was 
crosschecked within the health record audit phase of the study. Participant self-assessment of their socio eco-
nomic status (SES) of “Above Australian Average”, “Australian Average” and “Below Australian Average” 
were recorded. Stress levels were recorded via a visual analogue scale (VAS) of 0-100 with end points of “Not 
stressed at all” and “Highly stressed”. Participant body mass index (BMI) was calculated and coded according to 
Australian Government Health Guidelines categories of “underweight (<18.5)”, “normal weight (18.5 - 24.99)”, 
“overweight (25 - 29.99)” and “Obese (>30)”. Study period hours spent outdoors were calculated from partici-
pants’ nominated hours for each weekday and weekend day. Current smoking status was captured as a dichoto-
mised “yes”, “no” response.  
Immune modulating and suppressant medications (immune therapy medications, ITM): Methotrexate, Hy-
droxychloroquine, Prednisolone, Azathioprine, intravenous immunoglobulin, Dapsone and Mycophenolate were 
categorised as a single group to examine effect on SRF history in relation to FMSS use. Vitamin D supplemen-
tation, whilst considered by many to have properties of immune modulation [22]-[25], was considered sepa-
rately. 
2.3. Statistical Methods 
Due to over dispersion, a negative binomial regression model was used to assess the relationship between SRF 
days and FMSS usage days. Covariates considered were: participant age; diagnosis years; outdoors hours; SES; 
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BMI; stress; Vitamin D, hormones and ITM use. 
Initially, all variables of interest were included in the model with a backward stepwise approach to identify 
the best possible multivariate model. Interactions were tested for SRF days and covariates with significant ef-
fects at the <0.05 level retained in the model. All normality assumptions were verified by inspection of probabil-
ity plots and histograms of residuals. Associations were expressed as odds ratios with 95% confidence intervals. 
All analyses were performed with the use of STATA v11.0 (StataCorp LP, College Station, Texas, USA). 
3. Results 
A total of 159 personal health records were audited to confirm a SLE diagnosis based upon documented evi-
dence of the 11 ACR classification criteria [18]. Of these, 83 participants met the classification criterion of ≥4 
out of 11, and completed all components of the study. The structured interview process resulted in 3 participants 
reporting a SRF history of “constant flaring”; therefore these participants were excluded from final analysis. 
Health record audit showed a broad representation of SLE clinical manifestations with clinical features of malar 
rash, photosensitivity, arthritis, and presence of antinuclear antibodies being frequently documented.  
Table 1 represents the distribution of characteristics across the final 80 SLE participants. Participants’ mean 
age was 47.69 years and diagnosed with SLE for approximately 2 - 38 years (mean 7.7 years). The participant  
 
Table 1. Demographic characteristics.                                                              
 n Mean SD Range 95% CI 
Age (Years) 80 47.7 13.6 19 - 77 44.7 50.7 
Diagnosis (Years) 77 7.7 6.3 2 - 38 6.3 9.1 
Current health score (VAS scale)a 80 54.2 22.6 0 - 98 49.2 59.2 
Stress score (VAS scale)b 80 50.8 27.4 0 - 100 44.7 56.9 
Outdoor hours (Year) 80 490.6 433.2 0 - 2044 394.2 587.0 
n = 80 n % n = 80 n % 
Comorbidity   Body mass index   
Autoimmune Illness not SLE 43 53.8 Underweight 2 2.5 
Other illness not autoimmune 50 62.5 Normal 21 26.25 
Ethnic background   Overweight 33 41.25 
Caucasian 70 87.5 Obese 24 30.0 
Educational background   Smoking status   
Year 9 (15 years) 8 10.0 Current smoker 6 7.5 
School leaving certificate 24 30.0 Past smoker 30 37.5 
Higher school certificate 2 2.5 Use ITM 66 82.5 
Apprenticeship 4 5.0 Use Vitamin D supplement 24 30.0 
Tertiary (University/College) 36 45.0 Use hormone supplement 30 37.5 
Postgraduate studies 6 7.5 Regular sun 39 48.8 
Clinical SLE features   Regular sun + Sunscreen 30 76.9 
Malar rash 57 71.3 Socio economic status   
Discoid rash 3 3.8 Above average 15 18.8 
Photosensitivity 43 53.8 Average 56 70.0 
Oral/nasal ulcers 29 36.3 Below average 9 11.3 
Arthritis 63 78.8 ACR SLE classification criteria  
Serositis 20 25.0 4 criteria 26 32.5 
Renal disorder 37 46.3 5 criteria 24 30.0 
Neurological disorder 33 41.3 6 criteria 17 21.25 
Haematological disorder 39 48.8 7 criteria 7 8.75 
Immunologic disorder 27 33.8 8 criteria 4 5.0 
Antinuclear antibody 73 91.3 9 criteria 2 2.5 
+ve response to pharmaceutics 75 93.8    
aVisual Analogue Scale Score of 0 - 100—Current Health (0) Extremely Poor—(100) Excellent; bStress (0) Not stressed at all—(100) 
Highly stressed. 
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inclusion criteria did exclude persons with a diagnosis history less than 2 years duration. Over 62.5% of partici-
pants self-reported comorbidities. The majority of participants were not current smokers (92.5%) however, a 
larger number reported being past smokers (37.5%). Current smoking status was confirmed by serum cotinine 
assay and showed concordant results with self-report. 
The analysis also included data on the usage of ITM as well as supplementation of Vitamin D and hormonal 
treatments. Participant use of ITM was common (82.5%) with many being prescribed 2 or more ITMs. No as-
sessment of individual participant medication compliance was undertaken. 
Table 2 represents data in specific reference to SRF events and makeup product usage. Tabulated results 
showed that participants experienced a mean of 6.8 SRF events within the study year ranging from 0 flare events 
to 1 event per week. Counts of SRF days ranged 0 - 240 days with a mean count of 29.2 SRF days. Three par-
ticipants reported single events that equated to 60 - 90 SRF day counts. FM was used by 73.75% of the cohort 
and SS was used by 77.5%. Many participants used more than one FMSS product each day. SS usage in regards 
to regular sun exposure was explored with 49% reporting regular sun exposure (Table 1) and of those 76.9% 
responded as always wearing SS when in the sun. A range of 0 - 1223 (mean 291) total exposure days for over-
all FMSS category indicates multiple individual product usage within the study year.  
Negative binomial regression was used to model SRF days (outcome) against independent FMSS product 
variables as well as social, lifestyles and illness variables with results summarised within Table 3. Statistically  
 
Table 2. Self-reported flare (SRF) and makeup product (FMSS) usage.                                    
 n Mean SD Range 95% CI 
SRF no. (Year) 80 6.8 9.7 0 - 52 4.6 8.9 
SRF days (Year) 80 29.2 39 0 - 240 20.5 37.9 
FMSS exposure days 80 291.1 214.2 0 - 1223 243.4 338.7 
FMSS product count 80 1.6 0.9 0 - 7 1.4 1.8 
n = 80 n %  
Use of FM 59 73.8  
Use of SS 62 77.5  
 
Table 3. Negative binomial regression for flare days (Fc) and independent variables.                         
 OR p > |Z| 95% CI 
Univariate model (Fc)     
FMSS product days 0.998 0.01 0.998 1.0 
Immune therapy medications 1.968 0.03 1.088 3.56 
FM 0.58 0.04 0.35 0.96 
SS 0.79 0.43 0.45 1.40 
Vitamin D 1.51 0.10 0.93 2.45 
Hormone treatment 1.22 0.39 0.78 1.94 
Age 0.99 0.06 0.97 1.00 
Years of diagnosis 0.97 0.07 0.93 1.00 
Body mass index 1.23 0.78 0.28 5.41 
Smoking 1.61 0.27 0.69 3.73 
Stress 1.00 0.63 0.99 1.01 
Outdoor hours 1.0 0.10 1.0 1.00 
Regular sun 0.93 0.74 0.59 1.45 
Multivariate model (Fc)    
FMSS product days 0.998 0.00 0.997 1.0 
Immune therapy medication 2.11 0.01 1.161 3.835 
FM days 0.603 0.05 0.363 1.0 
Immune therapy medication 1.855 0.04 1.023 3.364 
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significant associations for independent variables were found for FMSS product days, ITM and FM use; but not 
for SS as a sub group analysis of the FMSS product days. The analysis was adjusted for age, diagnosis years, 
SES, BMI, smoking, stress, therapeutic supplements of vitamin D and hormone treatments, sunburn events, and 
outdoor hours in the study year. No confounding effect was found for any of these factors. 
Protective effects, as demonstrated by odds ratio values, were statistically significant on both univariate and 
multivariate analysis of FMSS product exposure days (OR 0.998, CI 0.997 - 1.0) and FM usage (OR 0.603, CI 
0.363 - 1.0). Surprisingly, significant associations consistent with increased SRF risk were seen in a univariate 
model for participants undertaking ITM (OR 1.968, p = 0.03). This ITM association was also retained within 
multivariate models for FMSS product days (OR 2.11, CI 1.161 - 3.835) and the sub analysis of FM days (OR 
1.855, CI 1.023 - 3.364). This is likely a reflection of selection bias in that those with more severe SLE are more 
likely to be prescribed ITM. 
Participant total SRF days as a function of FMSS exposure (with 95% CI) within the study year for partici-
pants undertaking ITM and also for those that are not on ITM are presented in Figure 1. A reduction of SRF 
days with usage of FMSS products was demonstrated, and was consistent regardless of the participant taking 
ITM or not. There were significantly more SRF days in individuals on ITM (p = 0.01) however overall reduction 
of SRF days with increased chemical exposure was not contingent upon ITM therapy. The model estimates that 
an SLE patient on ITM can potentially have reduction in SRF days experienced within a year by a factor of 
0.0015 (0.15%) with each day of increasing FMSS product exposure. Absolute FMSS product exposure ranges 
from 0 to ~600 exposure days: for every 100 days of additional FMSS product exposure, the lupus SRF inci-
dence rate drops by 14%. Across the exposure range, the risk drops by 59%-putting this in terms of risk reduc-
tion, the SRF incidence rate for FMSS exposure level equal to 600 days is over half that observed with an expo-
sure level equal to 0.  
4. Discussion 
This study found a statistically significant inverse association between SRF days and exposure to FMSS prod-
ucts defined as FM and SS. Results show those SRF days were reduced by a factor of 0.15% for each day of 
FMSS product exposure over the study year, indicating a protective component to FMSS product usage. The sub 
analysis of FMSS category with ITM usage indicates that the reduction of SRF days was not contingent on ITM 
use. This reduction in symptom exacerbation days ultimately has potential to improve quality of life in SLE pa-
tients. 
 
 
Figure 1. Self-reported flare (SRF) day events as a function of FMSS exposure days 
and immune therapy medication use for the study year, together with 95% confidence 
bands.                                                                 
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SLE flare days within this study were calculated from the lived health experience of the individual participant 
rather than clinical markers of symptom exacerbation. Total flare days were calculated using the number and 
average length of SRF in days. No assessments of SRF severity in regards to health and quality of life impacts 
were made; however, 3 participants recalled long periods of symptom activation and recovery of 60 - 90 days. 
Due to the retrospective nature of reporting, symptom exacerbation characteristics specific to a reported single 
SRF were not explored. However, the reported tendency of lupus patients to inaccurately attribute symptom 
fluctuations to flare events [26]-[29] would tend to create bias against detection of a significant association with 
product exposure. 
Within the study group, symptoms of malar and body rash, photosensitivity, joint pain and fatigue were 
widely reported as common flare symptoms (Table 1) and they also had a high impact on quality of life and 
body self-image. The health record audit found that the commonest symptoms included joint involvement (ar-
thritis 78.75%), malar rash (71.25%) and photosensitive reactions (54%). These rates are similar to other studies 
examining epidemiology of SLE and symptom exacerbation [2] [6] [14] [30] [31]; however, the reported rates of 
malar rash within these studies are lower than that found within our Australian study population. This could be a 
result of the study involving a homogeneous Caucasian population; UV exposure intensity within the Australian 
environment; and the high prescribed usage of a known photosensitizing pharmaceutical, Hydroxychloroquine, 
as a primary treatment within the study population.  
ITM usage (82.5%) was considered a potential confounder of the impact of FMSS product use; unexpectedly, 
our results indicate that ITM use presented an elevated risk of SRF activity (OR 2.11). It is likely that this is a 
reflection of selection bias in that those with more severe SLE illness experience more flare days as a result of 
flare frequency and intensity, requiring a management regime involving one or more ITM.  
SLE skin symptoms of malar rash, scarring and photosensitive reactions result as either an illness manifesta-
tion or pharmaceutical therapy side effect [32]. To better manage these symptoms and their impacts, clinicians 
and health educators offer self-management advice to adopt lifestyle practices that focus on sun protection 
measures [30] [33]-[35] and, if necessary, masking of skin irregularities through the application of physical dis-
guises such as makeup [36] [37]. Advice on reduction of UV exposure includes avoidance of long periods of UV 
exposure, wearing hats and sun protective clothing and regular topical application of physical and chemical UV 
filters and barriers in the form of lotions.  
Adherence to the use of sun protection in the form of SS use has been widely examined and it has been argued 
to be a sometimes ineffective sun protective measure due to the practise of selective use only when significant 
exposure activity is planned. This sporadic use can in fact lead to higher UV exposure [38] [39] from prolonged 
time periods spent within direct sunlight and other UV sources in living and work environments. Repeated mini 
exposures to UV radiation occurring from sunlight sources and from internal lighting systems of modern homes, 
offices and places of daily activity, has been estimated at as much as 80% of total lifetime exposure [32] leaving 
a photosensitive person vulnerable to adverse effects. The amount of incidental lifetime UV exposure indicates 
that daily application of visually appealing products containing UV protection capabilities as a prophylactic 
measure of UV protection may be more effective particularly in a photosensitive population.  
Vila et al. [35], in a SLE and sunlight exposure study, found many clinical outcomes significantly improved 
with use of photo protection measures. Specifically, patients who adhered to UV protective regimes had signifi-
cantly lower renal involvement, thrombocytopenia, hospitalisations, and reduced requirement for either in-
creased dosage or additional ITM. Our study, whilst not finding a significant association with the use of SS 
alone and SRF, did find health improvements in the form of reduced SRF days, with the use of FM alone as well 
as FMSS as a combined product group.  
SS use within the study group was reported at 77.5% which is double that of reported rates of use within the 
Australian NSW Health adult female population (34.6%) [40]. Comparison rates for the use of FM and SS 
across other SLE studies was limited due to the small number of studies; however, there are reported rates of 50% 
SS use within SLE patients in Puerto Rico [35], and 54.7% SS and 60.4% cosmetic use in a US based general 
population birth mothers study [41]. These rates suggest that our study population was more compliant with sun 
protection measures than the general Australian population or other international study populations.  
Commercial personal product manufacturers have increased the use of UV protective chemicals and physical 
barriers to improve product saleability and acceptability [30] [42]. UV protectors in products are commonly in 
the form of organic and physical inorganic chemicals such as Titanium Dioxide (TiO2), Zinc oxides (ZnO) and 
mineral pigments including mica and other oxides, which act to either block, reflect or scatter UVA and UVB 
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radiation limiting penetration. A wide range of personal care products label these agents within their product in-
gredients. Everyday products of shampoos, shower gels, face moisturisers, soaps, clothing, cleaning agents as 
well as common makeup products such as foundation makeup, contain at least one UV protective agent [31] 
[43]. 
The NHANES study reports that 96.8% of randomly selected urine samples were found to contain a UV pro-
tective chemical, Benzophenone-3, indicating widespread exposure to UV protectors as a result of daily activi-
ties. It is possible that the protective and significant association with FM and SS found in our study could be as-
sociated with the individual participant’s chemical use of other commercial agents, including undisclosed per-
sonal cosmetic and cleansing products. The ubiquitous use of UV filters and UV protection chemicals in every-
day cleaning and personal products could also result in additional unintentional UV protection via daily chores 
and hygiene habits [44].  
It is also proposed that the reported positive self-image that occurs with cosmetic coverage of disfiguring 
symptoms, such as malar rash, scarring and photosensitivity [30] [36] [37] [45] could also have resulted in im-
proved psychological wellbeing and quality of life within those participants and therefore reduced impacts of 
SLE symptoms and recorded flare days.  
Study Strengths and Weaknesses 
This study demonstrated that SRF day was reduced in this SLE cohort with exposure to FMSS products of FM 
and SS. This apparent protective aspect of FMSS product use was detected regardless of whether they were tak-
ing ITM as part of their illness management regime. The study provides pilot data within the context of a retro-
spective study that relies on self-reported participant assessment of exposure and flare events in a Caucasian 
population. The capacity to assess individual measures of actual exposure or day counts of symptom exacerba-
tion as defined as a “flare” event was not possible at this time. The lack of ethnic diversity within our Australian 
study population would reduce the capacity for extrapolation of results to the wider, more diverse international 
SLE population. 
Flare assessment was undertaken from a patient perspective with adherence to a strict protocol for documen-
tation; however, confirmation from clinical data did not occur. Hence, flare days were estimated across the study 
year based upon participant self-report and this may have resulted in an overestimation of actual days. However, 
this overestimation would be expected to create a bias against detection of a significant association with product 
exposure.  
Measurement bias within the assessment of product exposure process was minimised by adopting a process of 
crosschecking reported usage within two separate data collection tools (HCMPL and study specific question-
naire). The FMSS product category did not include other cosmetic and personal products that may contain sun-
screen agents, so it is possible that the effect we are noting within our study could be attributed in part to other 
products used routinely. It is unlikely that the reported findings represent recall bias as patients were asked about 
FM and SS use in the context of a long list of products with no indication of associations being tested. 
5. Conclusions 
This study has examined the effects of FMSS exposure and exacerbation of SLE symptoms as defined by “SRF 
days”. The study results have highlighted a protective effect of wearing FMSS products, in particular FM with 
or without additional SS products. However, this study has not demonstrated a conclusive link to any particular 
product chemical component due to the inability to refine: individual product chemical content or concentrations, 
or the potential effects of product chemical admixing.  
The study results indicate that the investigation of SLE illness behaviour in respect to everyday beauty prod-
ucts needs further exploration. Formulations and concentrations of product chemical components change readily 
to meet consumer and commercial demands reducing capacity for researchers to gauge exact causation links 
between chemical exposure and health risk.  
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